AZD0901
AZD0901 (CMG901) is an anti-CLDN18.2 antibody-drug conjugate. AZD0901 binds to CLDN18.2, undergoes internalization, disrupts microtubules, and causes direct cytotoxicity and bystander killing. AZD0901 induces ADCC and CDC through its retained IgG1 Fc. AZD0901 can be used in research on gastric or gastroesophageal junction adenocarcinoma and CLDN18.2-positive advanced solid tumors. AZD0901 consists of the antibody Sonesitatug (HY-P991026) and the toxin VcMMAE (HY-15575).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
|
CLDN18.2 |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
SMILES
N/A
-
Synonyms
CMG901
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- AZD0901
- CMG901
- AZD 0901
- AZD-0901
- CMG 901
- CMG-901
- Antibody-Drug Conjugates (ADCs)
- Claudin
- Microtubule/Tubulin
- Antibody-Drug Conjugates
- ADC
- ADCC
- CDC
- CLDN18.2
- IgG1 Fc
- MMAE
- advanced solid tumors
- antibody-drug conjugate
- bystander killing
- gastric or gastroesophageal junction adenocarcinoma
- microtubules
- Inhibitor
- inhibitor
- inhibit